Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Podoven
- Development stage
- Unknown
- Lead developer
- Epitech
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Podoven is a topical formulation developed by Epitech specifically for podological applications, including the management of foot vascular and venous conditions. The product utilizes ALIAmide (Autacoid Local Inflammation Antagonism) technology, primarily through the active ingredient **adelmidrol**, a synthetic analogue of the endogenous fatty acid amide palmitoylethanolamide (PEA). Podoven is designed to modulate mast cell hyper-reactivity and dermo-epidermal inflammation, which are often implicated in the symptoms of chronic venous insufficiency and other foot-related skin disorders. By acting as a PPAR-alpha agonist and stabilizing mast cells, the formulation helps to alleviate local edema, itching, and skin reactivity in the lower limbs.
- Brand names
- Podoven
- Other names
- PODOVEN
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on Podoven.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Podoven.